Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Why Regeneron's Results for Its COVID Antibody Therapy Won't Boost Sales Much
Why Regeneron's Results for Its COVID Antibody Therapy Won't Boost Sales Much
Why Regeneron's Results for Its COVID Antibody Therapy Won't Boost Sales Much
Submitted by
admin
on November 20, 2021 - 12:01pm
Source:
Motley Fool
News Tags:
Regeneron
Roche
COVID-19
antibodies
Headline:
Why Regeneron's Results for Its COVID Antibody Therapy Won't Boost Sales Much
snippet:
Regeneron and Roche reported great results for REGEN-COV as a COVID-19 prophylaxis.
The therapy could primarily benefit the subset of patients who are immunocompromised.
New COVID-19 pills from Pfizer and Merck could limit the market for REGEN-COV.
Do Not Allow Advertisers to Use My Personal information
